Asthma

In the first report of its kind, a recent study compiled Korean Health Insurance Review and Assessment Service data from 2002 to 2013 to evaluate a bidirectional association between asthma and migraines in Korean adults.

The FDA is now requiring a boxed warning for montelukast (Singulair) to strengthen the existing warning about the risk of neuropsychiatric events.

The product will be immediately launched with limited commercial qualities, and manufacturers expect that there will be a steady supply by the fourth quarter of 2020.

Results from a new retrospective analysis have shown that patients prescribed tiotropium bromide (Spiriva Respimat) inhalation spray 1.25 mcg experienced fewer asthma-related exacerbations when the treatment was added to a combination inhaled corticosteroid and long-acting beta2 agonist (ICS + LABA), compared with patients who received an increased dose of ICS + LABA.

Advancements in the understanding of asthma pathophysiology has led to the discovery of defined asthma phenotypes and targeted interventions involving novel biologic therapies.

A recent study demonstrated that budesonide-formoterol is superior to albuterol for as-needed exacerbation prevention in mild asthma.

Benralizumab is a monoclonal antibody that binds directly to the IL-5 receptor alpha on eosinophils and attracts natural killer cells to induce rapid depletion of eosinophils via programmed cell death.

Can MH safely take albuterol instead of levalbuterol?

The results of a study of almost 500,000 women indicate that taking paracetamol or other painkillers during pregnancy does not increase the risk of asthma in children.

Pivotal phase 3 trial results show benefits for once-daily fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI; Trelegy Ellipta) in patients with uncontrolled asthma compared with standard FF/VI (Breo Ellipta) therapy.

The results of a new study by George Washington University show that about 4 million children worldwide develop asthma annually because of nitrogen dioxide inhalation through air pollution.

The new phase 2 data for an investigational once-daily, fixed dose combination currently in development for the treatment of inadequately controlled asthma was presented at the 2019 Annual International Congress of the American Thoracic Society (ATS) in Dallas.

Pivotal phase 3 trial results show benefits for once-daily fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI; Trelegy Ellipta) in patients with uncontrolled asthma compared with standard FF/VI (Breo Ellipta) therapy.

Pharmacists have a great opportunity to educate patients about how to stay healthy and counsel those in need of symptom relief about their allergy treatment options.

Patients can breathe easier knowing that their local pharmacists are ideally positioned to help them manage their allegy, asthma and COPD conditions.

Previous research has found illicit opiates may exacerbate asthma.

Inhaler misuse may result in more asthma attacks.

Some may remember the old formulation of OTC Primatene Mist that was taken off the market in 2011 because it contained chlorofluorocarbon (CFC) propellants, which are known to deplete the ozone layer.

The FDA announced approval of Wixela Inhub on January 30, 2019.

Pulmatrix is set to launch a clinical investigation on the product in 2019.

With new products coming to the pharmacy market, such as smart devices and digital medicines, the profession will need to develop quickly to keep up pace.

Mylan's drug is approved for 100 mcg/50 mcg, 250 mcg/50 mcg, and 500 mcg/50 mcg doses.

The generic drug (Wixela Inhub, Mylan) is indicated to treat patients with asthma and chronic obstructive pulmonary disease, including bronchitis and emphysema.

Teva has just unveiled the world's first integrated smart inhaler to the market.

The FDA has approved dupilumab (Dupixent, Regeneron and Sanofi) in patients with moderate-to-severe asthma aged 12 years and older

The FDA has approved dupilumab (Dupixent, Regeneron and Sanofi) in patients with moderate-to-severe asthma aged 12 years and older.

The FDA has approved dupilumab (Dupixent®, Regeneron and Sanofi) as an add-on maintenance therapy in patients with moderate-to-severe asthma aged 12 years and older with an eosinophilic phenotype or with oral corticosteroid-dependent asthma.

Teva Pharmaceutical Industries Ltd has released Qvar Redihaler (beclomethasone dipropionate HFA).